Investment strategy

The financing strategy of the Company is based on the following principles;

• Value creation for our shareholders and stakeholders;
• Build on clinical and scientific milestones;
• Maximum leverage of public regional funding.

Cardio3 BioSciences raised more 26M€ since inception of which 13,7M€ in equity. The next financing round (Series C) should take place during the second quarter of 2010 based on the C-Cure

Stage A 3 months data. All proceeds are fully dedicated to clinical trials and the development of our product pipeline.

Our goal is to leverage on the equity to get access to regional funding to finance our research and development programs. As per December 2009, the company has secured public funding with the Walloon Region General Directorate for a total of 12,2M€ in recoverable cash advances. These funds, which bear no interest, become repayable on the commercialization of the outcome of the research funded. So far, all of the clinical, research and development programs are financed up to 70% by regional funding.